Last reviewed · How we verify
Memantine-matched Placebo capsule
This is a placebo capsule formulated to match memantine, an NMDA receptor antagonist used in Alzheimer's disease treatment.
This is a placebo capsule formulated to match memantine, an NMDA receptor antagonist used in Alzheimer's disease treatment. Used for Control arm in clinical trials (not a therapeutic agent).
At a glance
| Generic name | Memantine-matched Placebo capsule |
|---|---|
| Also known as | Sugar pill |
| Sponsor | University of Texas Southwestern Medical Center |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
As a placebo control, this capsule contains no active pharmaceutical ingredient and is designed to be indistinguishable from memantine capsules in clinical trials. Memantine itself works by blocking NMDA glutamate receptors to reduce excitotoxicity in the brain, but this matched placebo serves only as a control comparator in research studies.
Approved indications
- Control arm in clinical trials (not a therapeutic agent)
Common side effects
Key clinical trials
- Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus (PHASE2)
- Memantine for Epileptic Encephalopathy (PHASE4)
- Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial (PHASE3)
- Attenuation of Corticosteroid Induced Hippocampal Changes (PHASE4)
- The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study (PHASE2)
- Memantine-enhanced Buprenorphine Treatment for Opioid-dependent Young Adults (PHASE2, PHASE3)
- A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease (PHASE3)
- A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: